Vitrectomy for Branch Retinal Vein Occlusion

Shinjo Ophthalmologic Institute70 enrolled

Overview

To evaluate the long term outcomes of pars plana vitrectomy (PPV), with and without internal limiting membrane (ILM) peeling, in eyes with persistent macular edema secondary to branch retinal vein occlusion (BRVO). Results suggest the following hypothesis: * PPV, with and without ILM peeling, appears to be beneficial in eyes with persistent macular edema due to BRVO * Effectiveness is maintained long term * ILM peeling does not significantly affect postoperative best corrected visual acuity (BCVA)

Study Type

OBSERVATIONAL

Enrollment

Conditions

Vitrectomy

Interventions

Vitrectomy w/o ILM peeling for macular edema with BRVOPROCEDURE

Concurrent phacoemulsification and intraocular lens insertion in the capsular bag was performed, followed by PPV with separation of the posterior hyaloid from the optic disk and posterior retina with a posterior vitreous detachment was not present. Indocyanine green (ICG)-assisted peeling was performed in all consecutive patients between April 2000 and June 2003. 0.1% ICG solution was injected over the macular region. Immediately after application, the dye was washed out using a vitreous cutter. Repeated injection of ICG was not required. Triamcinolone acetonide (TA)-assisted ILM peeling was performed in all consecutive patients from July 2003 to November 2006.

Eligibility

Sex: ALLMin age: 45 YearsMax age: 86 Years

Medical Language ↔ Plain English

Inclusion Criteria: * duration of symptoms lasting 27 weeks Exclusion Criteria: * vitreous hemorrhage * severe cataract * biomicroscopic vitreomacular traction and epiretinal membrane * previous vitreoretinal surgery * other ocular diseases that could contribute to visual loss. * patients with macular branch vein occlusion * patients with a history of previous grid laser photocoagulation

Locations (1)

Shinjo Ophthalmologic Institute

Miyazaki, Miyazaki, Japan

Outcomes

Primary Outcomes

Reporting of the long term outcomes of PPV, with and without ILM peeling, in eyes with persistent macular edema secondary to BRVO

Time frame: 11 years

Secondary Outcomes

Elevate the effectiveness of ILM peeling

Time frame: 11 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.